Search Results - "Juergens, R.A."

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC by Melosky, B., Chu, Q., Juergens, R.A., Leighl, N., Ionescu, D., Tsao, M.-S., McLeod, D., Hirsh, V.

“…•Checkpoint inhibitors re-engage the immune system to fight cancer.•Survival benefits are confirmed for first- and later line advanced NSCLC.•Immune-related…”
Get full text

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort by Juergens, R A, Mariano, C, Jolivet, J, Finn, N, Rothenstein, J, Reaume, M N, Faghih, A, Labbé, C, Owen, S, Shepherd, F A, Villeneuve, J, Romeyer, F, Pettersson, F, Butts, C

“…Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit…”
Get full text

Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey by Yiu, K.C.Y, Juergens, R.A, Swaminath, A

Get full text

Immuno-oncology-the new paradigm of lung cancer treatment by Dawe, D E, Harlos, C H, Juergens, R A

“…Systemic therapy is an essential part of treatment for all patients with small-cell lung cancer (sclc) and for most patients with non-small-cell lung cancer…”
Get full text

474P - Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy by Hao, D., Ellis, P.M., Laurie, S.A., Juergens, R.A., Mates, M., Bradbury, P.A., Tsao, M., Tehfe, M., Kollmannsberger, C.K., Goffin, J.R., Wheatley-Price, P., Hilton, J., Robinson, A.G., Brown-Walker, P., Tu, D., Smoragiewicz, M., Seymour, L.K.

“…In this phase Ib multicenter study, we sought to characterize the PK, safety and tolerability of durvalumab (D), an anti-PD-L1 antibody, ± tremelimumab (T), an…”
Get full text

Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy by Hao, D., Ellis, P.M., Laurie, S.A., Juergens, R.A., Mates, M., Bradbury, P.A., Tsao, M., Tehfe, M., Kollmannsberger, C.K., Goffin, J.R., Wheatley-Price, P., Hilton, J., Robinson, A.G., Brown-Walker, P., Tu, D., Smoragiewicz, M., Seymour, L.K.

Get full text

Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC) by Chu, Q.S.-C., van Herpen, C., Leighl, N.B., Markman, B., Clarke, S., Juergens, R.A., Basciano, P., Lathers, D., Tannenbaum-Dvir, S., Urbanska, K., Kollia, G., Darby, C., Williams, D., Kolaitis, G., Ready, N.

Get full text

Management of EGFR- mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective by Cabanero, M, Sangha, R, Sheffield, B S, Sukhai, M, Pakkal, M, Kamel-Reid, S, Karsan, A, Ionescu, D, Juergens, R A, Butts, C, Tsao, M S

“…Starting in the early 2000s, non-small-cell lung cancer (nsclc) subtypes have evolved from being histologically described to molecularly defined. Management of…”
Get full text

Resource use in the last three months of life by lung cancer patients in southern Ontario by Wang, Y, Van Dam, A, Slaven, M, Ellis, K J, Goffin, J R, Juergens, R A, Ellis, P M

“…End-of-life cancer care involves multidisciplinary teams working in various settings. Evaluating the quality of care and the feedback from such processes is an…”
Get full text